(MENAFN- EIN Presswire)
CHICAGO, NY, UNITED STATES, January 17, 2025 /EINPresswire / -- The global inhaled nitric oxide
market , valued at $266.17 million in 2024, is set to witness significant growth, projected to attain a market size of $474.72 million by 2033. This growth will be achieved at a CAGR of 6.64% during the forecast period of 2025–2033, according to the latest market research.
The Request of this Sample Report Here:-
Inhaled nitric oxide is widely recognized for its therapeutic applications in managing respiratory conditions such as pulmonary hypertension and hypoxic respiratory failure, especially in neonatal and pediatric care. Its role as a vasodilator makes it a critical intervention for improving oxygenation and reducing pulmonary vascular resistance.
Market Dynamics
Driver: Growing Neonatal Care Expansions Prioritizing Inhaled Nitric Oxide for Enhanced Early-Life Critical Respiratory Support
Efforts to strengthen neonatal care worldwide are rapidly expanding the use of inhaled nitric oxide market, shining a spotlight on respiratory complications in the earliest stages of life. In 2023 alone, 18 newly built neonatal wards across Europe outfitted their facilities with cutting-edge iNO devices to manage conditions such as persistent pulmonary hypertension of the newborn. Hospitals in the Middle East have also recorded at least 3,000 neonatal iNO interventions every quarter, reflecting heightened vigilance in preventing long-term pulmonary damage. Meanwhile, advanced simulation labs in 25 pediatric centers in North America now feature iNO training modules for nurses and clinicians, ensuring proper handling and consistent delivery. A multicenter clinical registry reported that nearly 2,200 high-risk newborns showed improved oxygenation indices after iNO therapy, showcasing measurable patient benefits. Healthcare authorities in Asia are funding infrastructural upgrades across 15 pediatric research institutes, fueling cross-collaborative trials that refine iNO protocols for neonates, especially those with lower birth weights.
Driven by these escalating needs, many public health organizations in the inhaled nitric oxide market aim to subsidize inhaled nitric oxide solutions, amplifying accessibility in resource-constrained regions. Some philanthropic initiatives are delivering 5 new mobile iNO delivery carts to provincial maternity clinics in Africa, bridging disparities in neonatal care. At the same time, a wave of specialized respiratory devices has swept into smaller community hospitals, with 40 such facilities in Latin America reporting newly adopted iNO programs for neonatal ICUs. Leading academics have noted that integrating nitric oxide therapy reduces ventilator time for newborns by promoting faster improvement in arterial blood gases, thus decreasing complications linked to prolonged mechanical ventilation. Backed by real-world data, these collective efforts reinforce the significance of iNO in mitigating critical newborn health challenges and steering the market toward cutting-edge systems that adapt to the evolving needs of fragile patient populations.
For further insights and detailed market analysis, contact:-
Top Players in the Inhaled Nitric Oxide Market
.Air Liquide Healthcare
.Bellerophon Therapeutics
.Beyond Air
.Circassia Pharmaceuticals
.Getinge
.International Biomedical
.LINDE
.Mallinckrodt Pharmaceuticals
.Praxair (NoxBox)
.SLE
.Vero Biotech
.Other major players
Market Segmentation Overview
By System
.Cylinder Based System
.Electric System
.Chemical Based System
By Type
.Adults
.Pediatrics
By Components
.Hardware
.Mechanical Ventilator
.Flow Sensor
.Respiratory Circuits Connectors
.Nitric Oxide Container
.Nitric Oxide Analyzer
.Inlet & Outlet Pipe
.Digital Monitor
.Services
.Managed Services
.Professional Services
.Consulting
.Support & Maintenance
By Applications
.Pulmonary Hypertension
.Tuberculosis Treatment
.Malaria Treatment
.Chronic Obstructive Pulmonary Applications (COPD)
.Acute Respiratory Distress Syndrome (ARDS)
.Others
By End User
.Hospitals
.Clinics
.Ambulatory Centers
By Region
.North America
.The U.S.
.Canada
.Mexico
.Europe
.Western Europe
.The UK
.Germany
.France
.Italy
.Spain
.Rest of Western Europe
.Eastern Europe
.Poland
.Russia
.Rest of Eastern Europe
.Asia Pacific
.China
.India
.Japan
.Australia & New Zealand
.South Korea
.ASEAN
.Rest of Asia Pacific
.Middle East & Africa (MEA)
.Saudi Arabia
.South Africa
.UAE
.Rest of MEA
.South America
.Argentina
.Brazil
.Rest of South America
Download Sample PDF Report@-
About Astute Analytica:
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.
They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.
Aamir Beg
Astute Analytica
+1 888-429-6757
email us here
Visit us on social media:
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN17012025003118003196ID1109101898
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.